Cosmo Bio Company,Limited (TYO:3386)

Market Cap	7.30B +15.1%
Revenue (ttm)	10.77B +7.3%
Net Income	337.00M +28.6%
EPS	59.26 +31.5%
Shares Out	5.67M
PE Ratio	21.72
Forward PE	n/a
Dividend	50.00 (3.92%)
Ex-Dividend Date	Dec 29, 2025

Volume	1,200
Average Volume	8,150
Open	1,286.00
Previous Close	1,277.00
Day's Range	1,286.00 - 1,291.00
52-Week Range	971.00 - 1,486.00
Beta	0.08
RSI	47.15
Earnings Date	May 8, 2026

About Cosmo Bio Company,Limited

Cosmo Bio Company,Limited, together with its subsidiaries, engages in the purchase and sale of research reagents, equipment, and contract services related to life science worldwide. The company distributes antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, and bacteria, as well as detection reagents, cell and tissue culture systems, and gene analysis systems; and research instruments, including electrophoresis apparatuses, cell culture labware, ge...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1978
• Employees: 182
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 3386

Financial Performance

In 2025, Cosmo Bio Company,Limited's revenue was 10.77 billion, an increase of 7.26% compared to the previous year's 10.04 billion. Earnings were 337.00 million, an increase of 28.63%.